Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people stay on semaglutide for weight loss for as long as it continues to work and remains clinically appropriate — there is no fixed universal end date. In clinical trials, the treatment period ran to 68–72 weeks, but real-world prescribing decisions depend on your response, your health, and the guidance of your prescriber. Semaglutide (sold as Wegovy for weight management) is a prescription-only medicine, and a prescriber decides how long it is right for you based on your individual circumstances.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misconception about semaglutide for weight loss is that it works like an antibiotic, a defined course, then you stop. That is not how it works. Obesity is a chronic condition, and the medicines used to treat it are designed for long-term use in much the same way as treatments for high blood pressure or high cholesterol. The clinical trials that established semaglutide's effectiveness ran for over a year, and they showed clearly that stopping the medicine tends to reverse much of the benefit: a follow-up paper published alongside the STEP 1 trial in the New England Journal of Medicine found participants regained around two-thirds of their lost weight within a year of stopping. That is not a failure of willpower, it reflects what the medicine is doing biologically. So the honest answer to how long you stay on it is: until you and your prescriber decide, together, that stopping is the right move.
This matters because it changes how you should think about starting. It is not a quick fix followed by a return to baseline. It is a treatment you commit to, with clinical oversight throughout.
For patients accessing semaglutide through the NHS, NICE's technology appraisal TA875 sets a clear boundary: semaglutide should be used for a maximum of two years, delivered within a specialist weight management service that includes diet and activity support. If less than 5% weight loss is achieved after six months at the maintenance dose, continuing treatment should be reviewed. These conditions reflect the NHS commissioning framework, they apply to NHS prescriptions, not to private prescriptions, where the licensed indications and your prescriber's clinical judgement govern the decision.
Private prescribing follows the medicine's licence and your clinical response. There is no two-year ceiling written into the licence itself. What matters is that treatment continues to be appropriate, effective, and regularly reviewed. At nume, every repeat order is assessed by a GPhC-registered prescriber (not rubber-stamped, genuinely reviewed) before it is approved. Questions about your individual treatment length are exactly what those reviews are for, and if you want a fuller picture of how long you can stay on semaglutide and what governs that decision, we cover it in detail separately.
Understanding the timeline helps you set realistic expectations. After starting at 0.25mg and titrating upward every four weeks or so, meaningful weight loss usually becomes noticeable by weeks eight to twelve. The steepest rate of loss tends to occur in the first six to nine months, with results continuing but slowing as you approach your maintenance dose. The STEP 1 trial recorded an average reduction of around 15% of body weight over 68 weeks at the 2.4mg maintenance dose, and with the newer 7.2mg maintenance dose, approved by the MHRA in early 2026, trials reported approximately 20.7% average loss over 72 weeks.
A practical check you can do in under a minute: compare your weight today against your starting weight and calculate your percentage change, not just the number on the scale. A 10kg loss at 120kg is an 8.3% reduction, that context helps you and your prescriber assess whether treatment is tracking well. If you want to understand how the timeline of weight loss on semaglutide typically unfolds, there is more detail on that.
Because weight tends to return after stopping, your prescriber will want to discuss an exit strategy before you get there, not as a reason to avoid stopping, but as a reason to plan it properly. Gradual tapering, continued lifestyle changes, and clear follow-up all improve outcomes. Some people transition to a lower maintenance dose, and if you are considering a reduced amount rather than stopping altogether, our guide on how long you can microdose semaglutide explains what that approach involves and how long it can be sustained. Others reach a stable weight and jointly decide to stop with monitoring in place. There is no single right answer, and anyone who tells you otherwise is oversimplifying a complex clinical picture.
The question of how long Wegovy can be used and what comes after is one our prescribers discuss regularly. If you are weighing up your options, including cost over a longer treatment period, our Wegovy pricing page explains what is included in a private prescription with us. And if you are ready to talk through whether semaglutide is right for you, start your free consultation, a clinician will review your details the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.